F-Prime is a global venture firm investing across healthcare and technology, with a strategy centered on backing technically differentiated companies attacking large, complex markets. The firm is willing to take meaningful early risk, but only when strong domain expertise, credible validation, and a clear commercialization path support the opportunity.
Evaluation weights
How much weight this firm places on each dimension. Totals 100%.
Revenue, growth, and unit economics
Size, timing, and competitive landscape
Founder experience and execution ability
Differentiation and technical quality
- Bias toward vertical, domain-specific solutions over broad horizontal narratives
- Bias toward measurable proof over sector hype
- Willingness to accept technical risk when commercial path is credible
- Preference for regulated-market infrastructure with durable defensibility
Pitch difficulty
How hard it is to get a meeting and close funding from this firm.
- Funded / yr
- 37Deals closed in a typical year.
- Led / yr
- 11Rounds led in the last 12 months.
- Pitches / yr
- ~18044Decks reviewed in a typical year.
- Acceptance rate
- 0.2%Share of pitches that get funded.
Estimated — public data is not fully disclosed.
Why it's hard
- Strong emphasis on domain-expert founders and execution history
- Requires tangible validation such as pilots, revenue traction, or clinical data
- Avoids hype-driven markets without clear commercial proof
- Looks for step-change product or scientific differentiation, not incremental stories
F-Prime is open across multiple stages and will back early risk, but the bar is high on founder credibility, evidence of validation, and a concrete path to commercialization. Companies in speculative or weakly validated sectors are unlikely to advance.
Green flags
What drives a yes for this firm.
- Founders with deep domain expertise and a demonstrated execution track record
- Quantifiable market pain with clear ROI or clinical relevance
- Early validation such as pilot customers, enterprise usage, pre-clinical data, or milestone attainment
- Differentiated technical, product, or scientific advantage with defensible IP or workflow fit
- A credible go-to-market and commercialization path in a large market
Red flags
What kills deals and gets a fast no.
- No clear go-to-market path or vague commercialization plan
- Pitching a hype-heavy category without revenue, adoption, or clinical proof
- Incremental science or product improvement without step-change impact
- Founders lacking domain depth for a specialized or regulated market
- Technical ambition disconnected from customer ROI or clinical outcomes
How to win
Patterns that lead to successful pitches.
- Lead with founder-market fit and why this team is uniquely qualified
- Show quantified proof: pilots, enterprise usage, ROI, clinical data, or milestone attainment
- Make the commercialization path explicit, including buyer, workflow, and regulatory strategy
- Frame the company as a vertical or infrastructure solution in a large, inefficient market
- Demonstrate disciplined capital use and a credible path to scalable economics
Fund strategy & identity
Who they are and how they operate.
- Invests from Pre-Seed through Growth, with strongest activity from Seed to Series B
- Leads or co-leads rounds with conviction, especially at Seed and Series A
- Balances technical risk against commercial risk rather than avoiding risk outright
- Backs both life sciences platforms and applied technology infrastructure
- Uses larger checks where early proof and category potential justify ownership
Firm identity
Investment focus
Industries, themes, and typical ARR expectations.
Industries
Investment themes
Typical check by stage
Typical ARR by stage
Investment thesis
Core beliefs and strategy behind their investing approach.
F‑Prime’s investment thesis is built around two pillars—healthcare and technology—unified by a belief that technical excellence, strong operators, and large addressable markets generate lasting value. In healthcare, they invest across therapeutics, medtech, and health‑tech services without a fixed stage constraint, backing companies that show compelling pre‑clinical or early clinical data, clear IP, and a pathway to regulatory approval. Their backing of ARTBIO’s radiopharmaceutical platform exemplifies willingness to fund modality‑shifting science when outcome impact is clear. In technology, the focus is on enterprise software, fintech, and frontier areas such as robotics, where advances in AI, automation, or hardware costs can be turned into workflow‑integrated products. The firm prefers “vertical” solutions that solve specific productivity gaps and demonstrates disciplined capital efficiency. Geographically, F‑Prime is global, with offices in Cambridge, London, and San Francisco, and investments spanning the Americas, Europe, and Asia. They avoid hype‑driven segments lacking commercial traction—such as autonomous vehicles without revenue models—and steer away from projects that offer incremental scientific improvements without step‑change outcomes. The core belief is that value accrues to teams that pair differentiated technical or clinical advantage with measurable commercialization metrics and capital‑efficient growth.
Decision patterns
How they evaluate and make investment decisions.
F‑Prime’s investment decisions are anchored in an evidence‑driven framework that heavily weights the founding team’s domain expertise and execution track record. A compelling, quantifiable market need and early validation—whether through pilot customers in tech or pre‑clinical data in life sciences—are required before they commit capital. Traction is measured by concrete outcomes: product usage by large enterprises, clinical milestones, or clear ROI for services. Deal‑breakers include technologies with no clear go‑to‑market path, hype‑driven sectors lacking commercial proof (e.g., autonomous vehicles without revenue), and scientific programs that do not promise a step‑change in outcomes. The firm balances technical risk with commercial risk, favoring “vertical” solutions that can demonstrate early revenue or clinical impact while remaining open to backing exceptional teams at any stage.
Risk appetite
F‑Prime is comfortable leading early‑stage rounds and taking calculated technical risk, especially in life‑sciences where strong data, IP and experienced teams can justify pre‑clinical bets (e.g., ARTBIO). In technology, they back seeds with solid early customer traction and co‑lead later rounds when the unit economics are clear. Their fintech commentary shows a preference for “goldilocks” companies that grow steadily toward profitability, indicating a moderate‑aggressive stance rather than pure speculation. The firm’s check‑size range—from $250 K up to $30 M—combined with a high lead tendency at seed and Series A, underscores a willingness to commit significant capital early, but they pull back from ventures lacking a credible commercial pathway. Overall, their risk appetite is disciplined and lead‑oriented: aggressive on technical risk when scientific or product upside is evident, cautious on commercial risk that lacks clear ROI.
Notable investments
Key portfolio companies and why they fit the thesis.
- SnapdocsLeadVertical SaaS digitizing mortgage closings with AI-driven workflow; matches F-Prime’s vertical SaaS + payments/platform thesis.
- PatientPingLeadHealth-tech care-coordination platform lowering costs by connecting providers; fits F-Prime’s services/HCIT thesis. F-Prime led seed and co-led Series A.
- SpinwheelLeadFintech infrastructure providing high-coverage consumer liability data; aligns with F-Prime’s data/infra focus. F-Prime led the $30M Series A.
- KanastraLeadPrivate-credit infrastructure modernising capital-markets workflows; consistent with F-Prime’s capital-markets/infra thesis. F-Prime led the $30M Series B.
- VestwellLeadModern retirement platform for advisors; core fintech infrastructure theme. Series A led by F-Prime.
- Deal EngineLeadVertical SaaS for travel-industry deal management; aligns with F-Prime’s vertical software thesis. Seed round led by F-Prime.
- CurvanceLeadDeFi/liquidity infrastructure in crypto; fits F-Prime’s frontier/crypto focus. Strategic round co-led by F-Prime and Primal.
- FlywireGlobal payments infrastructure solving complex cross-border receivables; emblematic fintech/payments thesis. F-Prime was an early backer but did not lead disclosed rounds.
- ToastVertical SaaS + payments platform for restaurants; quintessential example of F-Prime’s vertical SaaS thesis. F-Prime participated in the first institutional round but did not lead.
Co-invested with
Other firms in this catalog who've backed the same companies.
Partners
Full firm roster — key partners, partners, and the wider team.
Key partners
Stephen Knight
President & Senior Managing Partner
F-Prime
Stephen Knight is President and Senior Managing Partner at F-Prime Capital, where he invests broadly across healthcare.
David Jegen
Managing Partner, Tech Fund
F-Prime
David Jegen is Managing Partner of F-Prime’s Tech Fund, investing at the intersection of fintech and enterprise software.
Alex Pasteur
Partner
F-Prime
Alex Pasteur is a London-based Partner at F-Prime Capital focused on therapeutics and life sciences.
Carl Byers
Partner
F-Prime
Carl Byers is a Partner at F-Prime Capital with significant operating experience in healthcare IT, including as a founding team member and CFO of athenahealth.
Rocio Wu
Partner
F-Prime
Rocio Wu is a San Francisco-based Partner at F-Prime Capital leading investments across AI, enterprise, and fintech.
Partners
Chong Xu
Partner
F-Prime
F-Prime partner focused on biopharma, medtech, company formation, and China healthcare opportunities.
Gaurav Tuli
Partner
F-Prime
Enterprise technology investor behind Threat Stack, RiskRecon, Protenus, Canary Technologies, and Funnel.
Carl Bradford Byers 🚑
Partner
F-Prime
F-Prime Partner and former athenahealth founding CFO investing in healthcare IT and digital health.
Sachin Patodia
Partner
F-Prime
Partner focused on crypto and emerging technology, after Fidelity Asset Management and Avon Ventures.
Nihal Sinha
Partner
F-Prime
London-based biotech and life sciences investor across Europe and the U.S.
Jessica Alston
Partner
F-Prime
Life sciences investor focused on biopharmaceutical and medical technology companies.
Brett Cook
Partner
F-Prime
F-Prime Partner investing in healthcare technology and services companies.
Robert Weisskoff
Senior Partner
F-Prime
Senior Partner and biosciences investor with academic, pharma, and medical-device experience.
Jon Lim
Managing Partner
F-Prime
Managing Partner leading F-Prime’s Healthtech + Services investment efforts.
Ketan Patel
Managing Partner
F-Prime
Managing Partner investing in therapeutics and medical device companies.
Team
Olivia Carlson
Senior Associate
F-Prime
F-Prime Senior Associate investing in healthcare technology and services.
Sarah Lamont
Senior Associate
F-Prime
F-Prime Senior Associate focused on early-stage fintech investments.
Bala Varadhan
Principal
F-Prime
Principal focused on early-stage crypto, blockchain and Web3 investments.
Jack Neureuter
Senior Associate
F-Prime
Senior Associate focused on early-stage crypto investments.
Kevin Chu
Principal
F-Prime
F-Prime healthcare Principal focused on therapeutics, medtech, and life science tools.
Anastasiya Sybirna, PhD
Senior Associate
F-Prime
Senior Associate on F-Prime's London healthcare investment team.
Raj Basak
Senior Associate
F-Prime
F-Prime Senior Associate focused on therapeutics, medtech, and life-science tools.
Jingwei Li
Senior Associate
F-Prime
Senior Associate investing in fintech and digital-asset infrastructure.
Erica Lee
Principal
F-Prime
Principal investing in healthcare technology and services.
Liam Maniscalco
Associate
F-Prime
F-Prime Associate focused on early-stage enterprise software and frontier technology.
Betsy Mulé
Principal
F-Prime
Principal investing in enterprise technology and robotics.
Martin Taylor
Principal
F-Prime
F-Prime Principal building and backing biotechnology companies.
Benjamin Gorman
Principal
F-Prime
Principal investing in early-stage enterprise software and AI.
Julia McDowell
Venture Partner
F-Prime
F-Prime Venture Partner investing in healthcare technology and services.
Sanjay Aggarwal
Venture Partner
F-Prime
F-Prime Venture Partner focused on physical AI, enterprise AI, and robotics.
Connie Li
Principal
F-Prime
Principal on F-Prime's life sciences team focused on biotechnology.
Abdul Abdirahman
Principal
F-Prime
Principal investing in early-stage B2B software, fintech, and vertical SaaS.
Chance Mathisen
Associate
F-Prime
Associate focused on early-stage enterprise software investments.
M. Jackson Wilkinson
Venture and Operating Partner
F-Prime
F-Prime Venture and Operating Partner supporting healthtech product, design, and engineering.
Nikhil Ananth
Principal
F-Prime
F-Prime Principal investing across healthcare and life-science subsectors.
Brian Yordy
Principal
F-Prime
Principal investing in biopharmaceutical and medical technology companies.
Tashy Rodgers
Associate
F-Prime
F-Prime life sciences associate focused on therapeutics and medtech.
Public voice
Notable statements and public positions.
- As the AV sector falls victim to an over‑emphasis on technological ambition and under‑emphasis on commercial viability, Vertical Robotics companies are attracting a new wave of talented founders, investment capital, and corporate interest.
- Despite the Q1 2026 sell‑off, we believe financial services providers will ultimately benefit more from AI than be disrupted by it.
- We had conviction around the founding team… so we put in a $2.5M seed during the pandemic in 2021.
Similar firms
Firms with overlapping stage and industry focus.
B Capital
0.2%
New Enterprise Associates
0.3%
Accel
0.5%